Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
Posted 30 May 2012 | By Alexander Gaffney, RAC
The US Food and Drug Administration (FDA) warned consumers on 29 May of counterfeit copies of Teva Pharmaceutical Industries' attention deficit hyperactive disorder (ADHD) drug Adderall, saying some consumers had obtained copies of the drug containing the incorrect active pharmaceutical ingredients (APIs) through an online pharmacy.
ADHD drugs like Adderall use a combination of APIs known as amphetamine salts. In the case of Adderall, the drug contains dextroamphetamine saccarate, amphetamine aspartate, dextroamphetamine sulfate, and amphetamine sulfate.
These drugs have been experiencing shortages since late 2011 thanks to a complicated web of supply controls. Because of its potential for abuse, amphetamine salts are controlled via a DEA-administered quota system which determines the medical need for a drug and then releases stock of the API to manufacturers.
Critics maintain the system has directly led to shortages of the drug by under-assessing the medical need for the drug, while DEA has fired back saying blame lies solely with industry and its manufacturing and distribution choices.
Regardless of the true cause of the shortages, the situation has consumers looking to find stock of the drug wherever possible. For some, this involves traveling to numerous pharmacies in the hope of finding available supplies of the drug. For an increasing amount of other consumers, this involves going online in the hopes of bypassing pharmacies altogether.
And therein lies the root of the counterfeit Adderall, says FDA.
"Rogue websites and distributors may especially target medicines in short supply for counterfeiting," wrote FDA in a press release. Its findings add to research released in February in the International Journal of Clinical Practice, which found much of the rise in counterfeiting was attributable to consumers' use of online pharmacies.
"Although many consumers acknowledge some degree of risk with purchasing medications via the Internet, speed, convenience and cost often prompt these purchases," said Dr. Graham Jackson, author of the study.
In the case of counterfeit copies of Teva's Adderall, not only are the counterfeit medicines fraudulently sourced, but they also fail to contain the correct API's. Instead of containing the combination of amphetamine salts, the counterfeit medicines contain a combination of tramadol and acetaminophen, which FDA notes "are ingredients in medicines used to treat acute pain."
FDA also explained the counterfeits in question did not appear to be particularly sophisticated. Counterfeit copies of the drug were of the incorrect color, had incorrect markings and contained numerous misspellings on its packaging.
Read more:
FDA - FDA warns consumers about counterfeit version of Teva's Adderall
Regulatory Focus - ADHD Drugs Remain in Short Supply
Tags: Online Pharmacy, Adderall, Counterfeit, Shortages, Teva, amphetamine salts, ADHD, DEA, Latest News
Regulatory Focus newsletters
All the biggest regulatory news and happenings.